The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-13. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual description varies by batch |
| Solubility | Freely soluble in water | Aqueous buffers are commonly used |
| Typical storage temperature | -20 °C or below for powder | Reconstituted liquid kept at 2-8 °C short term |
| Purity method | Reversed-phase HPLC | Value derived from peak area integration |
| Identity method | Mass spectrometry | Confirms mass and sequence integrity |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
where the M over the arrow denotes that to conserve energy and momentum a third body is required (the molecularity of the reaction is three). Electron capture can be used in conjunction with chemical ionization. An electron capture detector is used in some gas chromatography systems.
=== Ultra-low temperature refrigerators === "Ultra-cold" or "ultra-low temperature (ULT)" (typically −80 or −86 °C [−112 or −123 °F]) freezers, as used for storing biological samples, also generally employ two stages of cooling, but in cascade. The lower temperature stage uses methane, or a similar gas, as a refrigerant, with its condenser kept at around −40 °C by a second stage which uses a more conventional refrigerant. For much lower temperatures, laboratories usually purchase liquid nitrogen (−196 °C [−320.8 °F]), kept in a Dewar flask, into which the samples are suspended. Cryogenic chest freezers can achieve temperatures of down to −150 °C (−238 °F), and may include a liquid nitrogen backup.
The Ms. Pat Show is an American television sitcom created by Jordan E. Cooper and Patricia "Ms. Pat" Williams that premiered on the streaming service BET+ on August 12, 2021. The show is based on the comedy and life story of comedian Ms. Pat as a convicted felon from the streets of Atlanta turned reluctant suburban mother. The series has received nominations for 4 Primetime Emmy Awards for Outstanding Directing for a Comedy Series.
Fluorescence microscopy using auramine O—a nucleic acid–binding fluorochrome—has largely replaced these techniques in clinical laboratories due to higher sensitivity, rapidity, and safety. Rhodamine, sometimes added as a secondary dye, contributes little to sensitivity but slightly enhances contrast.
=== Targeting the tricarboxylic acid cycle and glutaminolysis === The tricarboxylic acid cycle (TCA) and glutaminolysis can also be targeted for cancer treatment, since they are essential for the survival and proliferation of cancer cells. Ivosidenib and enasidenib, two FDA-approved cancer treatments, can arrest the TCA cycle of cancer cells by inhibiting isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), respectively. Ivosidenib is specific to acute myeloid leukemia (AML) and cholangiocarcinoma, whereas enasidenib is specific to just acute myeloid leukemia (AML). In a clinical trial consisting of 185 adult patients with cholangiocarcinoma and an IDH-1 mutation, there was a statistically significant improvement (p<0.0001; HR: 0.37) in patients randomized to ivosidenib. Still, some of the adverse side effects in these patients included fatigue, nausea, diarrhea, decreased appetite, ascites, and anemia. In a clinical trial consisting of 199 adult patients with AML and an IDH2 mutation, 23% of patients experienced complete response (CR) or complete response with partial hematologic recovery (CRh) lasting a median of 8.2 months while on enasidenib. Of the 157 patients who required transfusion at the beginning of the trial, 34% no longer required transfusions during the 56-day time period on enasidenib. Of the 42% of patients who did not require transfusions at the beginning of the trial, 76% still did not require a transfusion by the end of the trial.
Sources: en.wikipedia.org
Complementary to the field of structural genomics, protein structure prediction develops efficient mathematical models of proteins to computationally predict the molecular formations in theory, instead of detecting structures with laboratory observation. The most successful type of structure prediction, known as homology modeling, relies on the existence of a "template" structure with sequence similarity to the protein being modeled; structural genomics' goal is to provide sufficient representation in solved structures to model most of those that remain. Although producing accurate models remains a challenge when only distantly related template structures are available, it has been suggested that sequence alignment is the bottleneck in this process, as quite accurate models can be produced if a "perfect" sequence alignment is known. Many structure prediction methods have served to inform the emerging field of protein engineering, in which novel protein folds have already been designed. Many proteins (in eukaryotes ~33%) contain large unstructured but biologically functional segments and can be classified as intrinsically disordered proteins. Predicting and analysing protein disorder is an important part of protein structure characterisation.
The relationships at the base of the animal tree have been debated. Other than Ctenophora, the Bilateria and Cnidaria are the only groups with symmetry, and other evidence shows they are closely related. In addition to sponges, Placozoa has no symmetry and was often considered a "missing link" between protists and multicellular animals. The presence of hox genes in Placozoa shows that they were once more complex. The Porifera (sponges) have long been assumed to be sister to the rest of the animals, but there is evidence that the Ctenophora may be in that position. Molecular phylogenetics has supported both the sponge-sister and ctenophore-sister hypotheses. In 2017, Roberto Feuda and colleagues, using amino acid differences, presented both, with the following cladogram for the sponge-sister view that they supported (their ctenophore-sister tree simply interchanging the places of ctenophores and sponges):
Criterion 1: Generalized joint hypermobility, as measured by the Beighton score Criterion 2: Minimum two of the following must be met: Symptoms that suggest a difference in connective tissue structure Unusually soft or velvety skin Mild skin hyperextensibility Unexplained striae distensae or rubae at the back, groins, thighs, breasts, and/or abdomen in adolescents, men, or pre-pubertal women without a history of significant gain or loss of body fat or weight Bilateral piezogenic papules of the heel Recurrent or multiple abdominal hernia(s) Atrophic scarring involving at least two sites and without the formation of truly papyraceous and/or hemosideric scars as seen in classical EDS Pelvic floor, rectal, and/or uterine prolapse in children, men, or nulliparous women without a history of morbid obesity or other known predisposing medical condition Dental crowding and a high or narrow palate Arachnodactyly Arm span-to-height ratio ≥1.05 Mitral valve prolapse (MVP) mild or greater based on strict echocardiographic criteria Aortic root dilatation with Z-score >+2 Positive family history Proof that these symptoms interfere with daily life Musculoskeletal pain in two or more limbs, recurring daily for at least 3 months Chronic, widespread pain for ≥3 months Recurrent joint dislocations or frank joint instability, in the absence of trauma Criterion 3: Exclusion of all other possible connective tissue disorders that may be the root cause of symptoms.
=== Fibroplasia and granulation tissue formation === Simultaneously with angiogenesis, fibroblasts begin accumulating in the wound site. Fibroblasts begin entering the wound site two to five days after wounding as the inflammatory phase is ending, and their numbers peak at one to two weeks post-wounding. By the end of the first week, fibroblasts are the main cells in the wound. Fibroplasia ends two to four weeks after wounding. As a model the mechanism of fibroplasia may be conceptualised as an analogous process to angiogenesis (see above) - only the cell type involved is fibroblasts rather than endothelial cells. Initially there is a latent phase where the wound undergoes plasma exudation, inflammatory decontamination and debridement. Oedema increases the wound histologic accessibility for later fibroplastic migration. Second, as inflammation nears completion, macrophage and mast cells release fibroblast growth and chemotactic factors to activate fibroblasts from adjacent tissue. Fibroblasts at this stage loosen themselves from surrounding cells and ECM. Phagocytes further release proteases that break down the ECM of neighbouring tissue, freeing the activated fibroblasts to proliferate and migrate towards the wound. The difference between vascular sprouting and fibroblast proliferation is that the former is enhanced by hypoxia, whilst the latter is inhibited by hypoxia. The deposited fibroblastic connective tissue matures by secreting ECM into the extracellular space, forming granulation tissue (see below). Lastly collagen is deposited into the ECM.
Sources: en.wikipedia.org
The institution of psychiatry has attracted controversy since its inception. Scholars including those from social psychiatry, psychoanalysis, psychotherapy, and critical psychiatry have produced critiques. The critical psychiatry network provides criticisms from within the field of psychiatry. The term anti-psychiatry was coined by psychiatrist David Cooper in 1967 and was later made popular by Thomas Szasz. The word Antipsychiatrie was already used in Germany in 1904.
== Fifth Ministry == On 13 September 2006, following the 2006 election, a ministry of 19 cabinet ministers and 11 parliamentary secretaries was sworn in. It served until the end of the Ministry on 13 September 2007 following Anna Bligh's ascension to the post of Premier, and was followed by the Bligh Ministry. Linda Lavarch, the Attorney-General, resigned from the Ministry on 18 October 2006 citing depression. Kerry Shine and Margaret Keech assumed her portfolios on 1 November 2006. Craig Wallace was appointed to the available place within the Ministry.
== Chemical properties == Bromo(I) fluorosulfonate is a blackish-red, viscous, hydrolysis-sensitive liquid that reacts violently with water. Upon cooling, it solidifies into a glassy state. Bromo(I) fluorosulfonate reacts with iodine(I) fluorosulfonate at temperatures above 50 °C to form dibromoiodofluorosulfonate:
Sources: en.wikipedia.org
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.
Mass spectrometry is the standard confirmation of molecular mass and acetylation state. Chromatography establishes purity but does not identify the molecule on its own. The two techniques are normally applied together during verification.
No, because the reported value reflects the detection method and wavelength used, which vary between laboratories. A number stated without method details cannot be compared directly with another supplier's figure. Requesting the chromatogram and the method conditions is a common way to interpret it.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.